Alexandra Dinis

Dr. Alexandra Dinis

Hospital Pediátrico de Coimbra, CHUC
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Cell
Verified
Journal Article
Closed access
SZShen-Ying Zhang
Shen-Ying Zhang
NCNathaniel E. Clark
Nathaniel E. Clark
CFCatherine A. Freije
Catherine A. Freije
EPElodie Pauwels
Elodie Pauwels
ATAllison J. Taggart
Allison J. Taggart
JCJean-Laurent Casanova
Jean-Laurent Casanova

Verified
Journal Article
Open access
PDF file
ISInês Serrenho
Inês Serrenho
Miguel RosadoMiguel Rosado
Miguel Rosado
ADAlexandra Dinis
Alexandra Dinis
CCCarla Cardoso
Carla Cardoso
Mário GrãosMário Grãos
Mário Grãos
GBGraça Baltazar
Graça Baltazar
Neonatal hypoxic-ischemic encephalopathy (HIE) is an important cause of mortality and morbidity in the perinatal period. This condition results from a period of ischemia and hypoxia to the brain of neonates, leading to several disorders that profoundly affect the daily life of patients and their families. Currently, therapeutic hypothermia (TH) is the standard of care in developing countries; however, TH is not always effective, especially in severe cases of HIE. Addressing this concern, several preclinical studies assessed the potential of stem cell therapy (SCT) for HIE. With this systematic review, we gathered information included in 58 preclinical studies from the last decade, focusing on the ones using stem cells isolated from the umbilical cord blood, umbilical cord tissue, placenta, and bone marrow. Outstandingly, about 80% of these studies reported a significant improvement of cognitive and/or sensorimotor function, as well as decreased brain damage. These results show the potential of SCT for HIE and the possibility of this therapy, in combination with TH, becoming the next therapeutic approach for HIE. Nonetheless, few preclinical studies assessed the combination of TH and SCT for HIE, and the existent studies show some contradictory results, revealing the need to further explore this line of research.

1 October 1999 in Journal of Medical Genetics
Verified
Journal Article
Open access
PDF file
JSJorge M Saraiva
Jorge M Saraiva
ADAlexandra Dinis
Alexandra Dinis
CRCristina Resende
Cristina Resende
EFEmília Faria
Emília Faria
CGClara Gomes
Clara Gomes
NFNicolau da Fonseca
Nicolau da Fonseca
Immuno-osseous dysplasia is characterised by spondyloepiphyseal dysplasia, lymphopenia with defective cellular immunity, and progressive renal disease. We describe a patient with a severe form of the disease, review the features of another 24 patients, and discuss the previous classification. The differences between the two groups are not striking, and although similarities are greater between affected sibs, the same diagnosis of Schimke immuno-osseous dysplasia should apply to them all. The aetiology and physiopathology of this rare osteochondrodysplasia of presumed autosomal recessive inheritance remain unknown.

4 July 2016 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
PLPedro Louro
Pedro Louro
LRLina Ramos
Lina Ramos
CRConceição Robalo
Conceição Robalo
CCCândida Cancelinha
Cândida Cancelinha
ADAlexandra Dinis
Alexandra Dinis
PGPaula Garcia
Paula Garcia

Verified
Journal Article
Open access
PDF file
ISInês Serrenho
Inês Serrenho
CCCarla Cardoso
Carla Cardoso
MGMário Grãos
Mário Grãos
ADAlexandra Dinis
Alexandra Dinis
Bruno ManadasBruno Manadas
Bruno Manadas
GBGraça Baltazar
Graça Baltazar
Neonatal hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of death and long-term disability in the perinatal period. Currently, therapeutic hypothermia is the standard of care for this condition with modest efficacy and strict enrollment criteria. Therapy with umbilical cord blood cells (UCBC) has come forward as a strong candidate for the treatment of neonatal HIE, but no preclinical studies have yet compared the action of UCBC combined with hypothermia (HT) with the action of each therapy by itself. Thus, to evaluate the potential of each therapeutic approach, a hypoxic-ischemic brain lesion was induced in postnatal day ten rat pups; two hours later, HT was applied for 4 h; and 24, 48, and 72 h post-injury, UCBC were administered intravenously. The neonatal hypoxic-ischemic injury led to a brain lesion involving about 48% of the left hemisphere that was not improved by HT (36%) or UCBC alone (28%), but only with the combined therapies (25%; p = 0.0294). Moreover, a decrease in glial reactivity and improved functional outcomes were observed in both groups treated with UCBC. Overall, these results support UCBC as a successful therapeutic approach for HIE, even when treatment with therapeutic hypothermia is not possible.

1 January 2023 in Journal of Investigative Medicine High Impact Case Reports
Verified
Journal Article
Open access
JPJoana Pereira-Nunes
Joana Pereira-Nunes
MMMiguel Madureira
Miguel Madureira
ADAlexandra Dinis
Alexandra Dinis
HBHelena Barroca
Helena Barroca
JLJorge Lima
Jorge Lima
MBMaria Do Bom-Sucesso
Maria Do Bom-Sucesso
Kaposiform lymphangiomatosis (KLA) is a rare and aggressive generalized lymphatic anomaly (GLA), with distinctive clinical, radiology, morphologic, and genetic features. It does not have a current standard treatment and presents poor overall prognosis. Somatic mutations in the RAS pathway were reported as the likely driver for the majority of patients. We report a case of a 17-year-old male adolescent who was referred to the emergency department due to a severe anemia. Laboratory workup confirmed the anemia and revealed coagulation factor consumption and fibrinolysis. Chest-abdomen-pelvis computed tomography revealed an extensive cervical, mediastinal, abdominal and retroperitoneal “hematoma.” During admission, progressive pancytopenia, and disseminated intravascular coagulation were observed, and the hypothesis of a tumor/neoplastic etiology was considered. A thoracoscopy revealed a moderate hemorrhagic pleural effusion and a mediastinal mass resembling a “hemolymphangiomatosis” malformation, which was biopsied. Histology displayed a lymphatic-venous malformation. The patient was presented at the multidisciplinary Vascular Anomalies Center and, due to the complex vascular anomaly diagnosis, oral sirolimus monotherapy was initiated. Four years later, the patient remains clinically stable, with stability of the lesion’s dimensions and characteristics. A p.Q61R variant in the NRAS gene [NM_002524.4: c.182A>G, p.(Gln61Arg)], with 5% allelic fraction and 1993x coverage was detected. In conjunction with clinical and pathological findings, it allowed KLA final diagnosis. This case reinforces the importance of a high index of clinical suspicion and highlights the need of referring these cases to referral to Vascular Anomalies Centers.